Update on intra-arterial chemotherapy for retinoblastoma.

Mario Zanaty, Guilherme Barros, Nohra Chalouhi, Robert M Starke, Philip Manasseh, Stavropoula I Tjoumakaris, Carol L Shields, David Hasan, Ketan Bulsara, Robert H Rosenwasser, Pascal Jabbour

Journal: TheScientificWorldJournal 2015;2014():869604

PMID: 25405236

Free Full Text on PubMed Central View on PubMed

Abstract

The tools for managing retinoblastoma have been increasing in the past decade. While globe-salvage still relies heavily on intravenous chemotherapy, tumors in advanced stage that failed chemotherapy are now referred for intra-arterial chemotherapy (IAC) to avoid enucleation. However, IAC still has many obstacles to overcome. We present an update on the indications, complications, limitations, success, and technical aspects of IAC. Given its safety and high efficacy, it is expected that IAC will replace conventional strategies and will become a first-line option even for tumors that are amenable for other strategies.

Address: Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, PA 19107, USA.; Department of Neurosurgery, University of Virginia, Charlottesville, VA 22908, USA.; Department of Ophthalmology, Thomas Jefferson University Hospital, Philadelphia, PA 19017, USA.; Department of Neurosurgery, University of Iowa School of Medicine, Iowa City, IA 52242, USA.; Department of Neurosurgery, Yale University School of Medicine, New Haven, CT 06510, USA.; Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, PA 19107, USA ; Department of Neurological Surgery, Division of Neurovascular Surgery and Endovascular Neurosurgery, Thomas Jefferson University Hospital, 909 Walnut Street, 2nd Floor, Philadelphia, PA 19107, USA.

DOI: 10.1155/2014/869604

Link outs

Free resources

Full Text Sources:

Other Literature Sources:

https://scite.ai/reports/25405236

Miscellaneous:

https://assays.cancer.gov/CPTAC-68

MeSH Terms: Antineoplastic Agents, Child, Eye Enucleation, Humans, Infusions, Intra-Arterial, Melphalan, Ophthalmic Artery, Retinal Neoplasms, Retinoblastoma, Salvage Therapy, Treatment Outcome